1-[(6-chloropyridazin-3-yl)methyl]-8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 1312441-21-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-[(6-chloropyridazin-3-yl)methyl]-8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: 1-[(6-chloropyridazin-3-yl)methyl]-8-fluoro-4-oxoquinoline-3-carboxylic acid
• CAS: 1312441-21-6
• 化学式: C₁₅H₉ClFN₃O₃
• 分子量: 333.706
• InChiKey: ADMYXSOWQHDNEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  83.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-[(6-chloropyridazin-3-yl)methyl]-8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 、 3-甲磺酰基苯硼酸 在 二(三叔丁基膦)钯 、 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 0.17h， 生成 8-Fluoro-1-[[6-(3-methylsulfonylphenyl)pyridazin-3-yl]methyl]-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  Pyridine containing M1 positive allosteric modulators with reduced plasma protein binding

  摘要：

  Incorporation of pyridines and diazines into the biphenyl region of quinolone carboxylic acid derived M-1 positive allosteric modulators was investigated as a means of lowering plasma protein binding to enhance CNS exposure. (C) 2009 Elsevier Ltd. All rights reserved. Increased

  DOI：

  10.1016/j.bmcl.2009.11.059
• 作为产物：
  描述：

  在 lithium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-[(6-chloropyridazin-3-yl)methyl]-8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  Pyridine containing M1 positive allosteric modulators with reduced plasma protein binding

  摘要：

  Incorporation of pyridines and diazines into the biphenyl region of quinolone carboxylic acid derived M-1 positive allosteric modulators was investigated as a means of lowering plasma protein binding to enhance CNS exposure. (C) 2009 Elsevier Ltd. All rights reserved. Increased

  DOI：

  10.1016/j.bmcl.2009.11.059

文献信息

• 4-OXO,1-4-DIHYDROQUINOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Kuduk Scott D.

  公开号：US20110077220A1

  公开（公告）日：2011-03-31

  The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)化合物，其是M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包含该化合物的药物组合物，并且涉及使用该化合物和组合物治疗由M1受体介导的疾病。
• 4-OXO,1-4-dihydroquinoline M1 receptor positive allosteric modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08293914B2

  公开（公告）日：2012-10-23

  The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的化合物，它们是M1受体正向变构调节剂，并且在M1受体参与的疾病治疗中有用，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及含有这些化合物的制药组合物，以及利用这些化合物和组合物治疗M1受体介导的疾病的使用。
• [EN] 4-OXO-1,4-DIHYDROQUINOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS POUR LE RÉCEPTEUR M1 DE 4-OXO-1,4-DIHYDROQUINOLÉINE
  申请人：MERCK & CO INC

  公开号：WO2009134668A3

  公开（公告）日：2009-12-30
• US8293914B2
  申请人：——

  公开号：US8293914B2

  公开（公告）日：2012-10-23
• Pyridine containing M1 positive allosteric modulators with reduced plasma protein binding
  作者：Scott D. Kuduk、Christina N. Di Marco、Victoria Cofre、Daniel R. Pitts、William J. Ray、Lei Ma、Marion Wittmann、Matthew Seager、Kenneth Koeplinger、Chuck D. Thompson、George D. Hartman、Mark T. Bilodeau

  DOI：10.1016/j.bmcl.2009.11.059

  日期：2010.1

  Incorporation of pyridines and diazines into the biphenyl region of quinolone carboxylic acid derived M-1 positive allosteric modulators was investigated as a means of lowering plasma protein binding to enhance CNS exposure. (C) 2009 Elsevier Ltd. All rights reserved. Increased